Preview

Научно-практическая ревматология

Расширенный поиск

Антифосфолипидный синдром: диагностика и клинические проявления (лекция)

https://doi.org/10.14412/1995-4484-2014-56-71

Аннотация

В лекции приведены сведения об этиологии, патогенезе антифосфолипидного синдрома (АФС), генетической предрасположенности к его развитию. Представлены последние международные критерии диагностики AФC и его варианты. Данный синдром в зависимости от локализации тромбоза может поражать несколько систем органов, поэтому проблема AФC в наше время является мультидисциплинарной. Клинические проявления АФС достаточно общие (тромбозы различной локализации), поэтому диагноз может быть верифицирован только при наличии антифосфолипидных антител. Рассмотрена дифференциальная диагностика АФС.

Об авторе

Т. М. Решетняк
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия
Россия


Список литературы

1. <div><p>Насонов ЕЛ, редактор. Антифосфолипидный синдром. Москва: Литтерра; 2004. 424 с. [Nasonov EL, redaktor. Antifosfolipidnyi sindrom. Moscow: Litterra; 2004. 424 p.]</p><p>Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classifi cation criteria for defi nite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. DOI: 10.1111/j.1538-7836.2006.01753.x.</p><p>Erkan D, Pierangeli SS, editors. Antiphospholipid syndrome: insights and highlights from the 13th International Congress on Antiphospholipid Antibodies. New York: © Springer Science+Business Media; 2012. DOI 10.1007/978-1-4614-3194-7_17.</p><p>Asherson RA, Cervera R, Piette J-Ch, Shoenfeld Y, editors. The antiphospholipid syndrome II: Autoimmune thrombosis. New York: Elsevier; 2002. 3–445.</p><p>Решетняк ТМ. Антифосфолипидный синдром: диагноз и принципы терапии. Сonsilium medicum. 2002;(4):408–15. [Reshetnyak TM. Antifosfolipidnyi sindrom: diagnoz i printsipy terapii. Сonsilium medicum. 2002;(4):408–15.]</p><p>Khamashta MA, editor. Hughes Syndrome: Antiphospholipid syndrome. London: Springer; 2000. 463 p.</p><p>Cervera R, Piette JC, Font J, et al.; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27. DOI: http://dx.doi.org/10.1002/art.10187.</p><p>Решетняк ТМ, Вавилова ТВ. Клинико-лабораторные критерии антифосфолипидного синдрома – что нужно знать практическому врачу (Лекция). Клиническая лабораторная диагностика. 2010;(11):13–20. [Reshetnyak TM, Vavilova TV. Clinical and laboratory criteria for diagnosing the antiphospholipid syndrome: what is it important for the practitioner to know (a lecture). Klinicheskaya laboratornaya diagnostika. 2010;(11):13–20.]</p><p>Meroni PL, Riboldi P. Pathogenetic mechanism mediating antiphospholipid syndrome. Curr Opin Rheumatol. 2001;13(5):377–82. DOI: http://dx.doi.org/10.1097/00002281-200109000-00006.</p><p>Rauch J, Dieude M, Subang R, Levine JS. The dual role of innate immunity in the antiphospholipid syndrome. Lupus. 2010 Apr;19(4):347–53. DOI: 10.1177/0961203310361492.</p><p>Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33. DOI: 10.1056/NEJMoa021933.</p><p>Roubey RA. Immunology of the antiphospholipid antibody syndrome (Review). Arthritis Rheum. 1996;39(9):1444–54. DOI: http://dx.doi.org/10.1002/art.1780390903/.</p><p>Макацария АД, Саидова РА, Бицадзе ВО и др. Антифосфолипидный синдром. Макацария АД, Саидова РА, редакторы. Гормональная контрацепция и тромбофилические состояния. Москва: Триада Х; 2004. [Makatsariya AD, Saidova RA, Bitsadze VO, et al. Antifosfolipidnyi sindrom. Makatsariya AD, Saidova RA, redaktory. Gormonal'naya kontratseptsiya i trombofilicheskie sostoyaniya. Moscow: Triada Kh; 2004.]</p><p>Lockshin MD. Update on antiphospholipid syndrome. Bull NYU Hosp Jt Dis. 2008;66(3):195–7.</p><p>Rosendaal FR. Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb Haemost. 1997;78(1):1–6.</p><p>Решетняк ТМ. Антифосфолипидный синдром: современное состояние и задачи на будущее. Научно-практическая ревматология. 2013;51(1):11–14. [Reshetnyak TM. Antiphospholipid syndrome: state-of-the-art and future tasks. Rheumatology Science and Practice. 2013;51(1):11–14. DOI: http://dx.doi.org/10.14412/1995-4484-2013-1194.]</p><p>Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61(1):29–36. DOI: http://dx.doi.org/10.1002/art.24232.</p><p>Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009;68(3):397–9. DOI: http://dx.doi.org/10.1136/ard.2008.096669.</p><p>Kaiser R, Cleveland C, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009;68(2):238–41. DOI: http://dx.doi.org/10.1136/ard.2008.093013.</p><p>Tektonidou MG, Ioannidis JPA, Boki KA, et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndome. Q J Med. 2000;93(8):523–30. DOI: http://dx.doi.org/10.1093/qjmed/93.8.523.</p><p>Александрова ЕН, Решетняк ТМ, Новиков АА.</p><p>Иммунологическая характеристика антифосфолипидного синдрома. Клиническая лабораторная диагностика. 2005;9:12a. [Aleksandrova EN, Reshetnyak TM, Novikov AA. Immunologicheskaya kharakteristika antifosfolipidnogo sindroma. Klinicheskaya laboratornaya diagnostika. 2005;9:12a.]</p><p>Pengo V, Tripodi A, Reber G, et al. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientifi c and standardisation committee of the international society on thrombosis and haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737–40. DOI: http://dx.doi.org/10.1111/j.1538-7836.2009.03555.x.</p><p>Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237–42. DOI: http://dx.doi.org/10.1111/j.1538-7836.2009.03674.x.</p><p>Mateo J, Oliver A, Borrel M, et al. Laboratory evalution and clinical characyteristics of 2132 consecutive unselected patients with venous thromboembolism – results of the Spanish Multicentric Study on Thromboembolism (EMET-Study). J Thromb Haemost. 1997;77(3):444–51.</p><p>Asherson RA. New subsets of the antiphospholipid syndrome in 2006: ”PRE-APS” (probable APS) and microangiopathic antiphosppholipid syndromes (“MAPS”). Autoimmun Rev. 2006;6(2):76–80. DOI: http://dx.doi.org/10.1016/j.autrev.2006.06.008.</p><p>Asherson RA, Cervera R, Shepshelovich D, Shoenfeld Y (editorial). Nonthrombotic Manifestations of the antiphospholipid syndrome: away from thrombosis? J Rheum. 2006;33(6):1038–44.</p><p>Asherson RA. Pierangeli S, Cervera R. Is there a microangipathic antiphospholipid syndrome? Ann Rheum Dis. 2007;33(6):429–32.</p><p>Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome. Where do we stand? Arthritis Rheum. 2003;48(12):3320–7. DOI: http://dx.doi.org/10.1002/art.11359.</p><p>Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2003;5(5):395–400. DOI: http://dx.doi.org/10.1007/s11926-003-0031-7.</p><p>Решетняк ТМ, Александрова ЕН, Штивельбанд ИБ, Раденска-Лоповок СГ. Катастрофический антифосфолипидный синдром: диагностика и терапия. Терапевтический архив. 2005;77(5);41–7. [Reshetnyak ТМ, Aleksandrova EN, Shtivelband IВ, Radenska-Lopovok SG. Сatastrophic antiphospholipid syndrome: diagnosis and treatment. Terapevticheskii arkhiv. 2005;77(5);41–7.]</p><p>Bucciarelli S, Cervera R, Espinosa G, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev. 2006;6(2):72–5. DOI: http://dx.doi.org/10.1016/j.autrev.2006.06.007.</p><p>Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med. 1998;104(4):381–5. DOI: http://dx.doi.org/10.1016/S0002-9343(98)00061-8.</p><p>Kitchens CS, Erkan D, Brandao LR, et al. Thrombotic storm revisited: preliminary diagnostic criteria suggested by the Thrombotic Storm Study Group. Am J Med. 2011;124(4):290–6. DOI: http://dx.doi.org/10.1016/j.amjmed.2010.10.018.</p><p>Bayraktar UD, Erkan D, Bucciarelli S, et al. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007;34(2):346–52.</p><p>Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10(2):1074–9. DOI: http://dx.doi.org/10.1016/j.autrev.2010.08.005.</p><p>Erkan D, Asherson RA, Espinosa G, et al. The long-term outcome of catastrophic antiphos- pholipid syndrome survivors. Ann Rheum Dis. 2003;62(6):530–5. DOI: http://dx.doi.org/10.1136/ard.62.6.530.</p><p>Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Arthritis Rheum. 1996;39(1):9–22. DOI: http://dx.doi.org/10.1002/art.1780390103.</p><p>Joseph J, Scopelitis E. Seronegative antiphospholipid syndrome associated with plasminogen activator inhibitor. Lupus. 1994;3(3):201–3. DOI: http://dx.doi.org/10.1177/096120339400300312.</p><p>Калашникова ЛА. Неврология антифосфолипидного синдрома. Москва: Медицина; 2003. 256 с. [Kalashnikova LA. Nevrologiya antifosfolipidnogo sindroma. Moscow: Meditsina; 2003. 256 p.]</p><p>Решетняк ТМ, Алекберова ЗС, Александрова ЕН и др. Клинические аспекты антифосфолипидного синдрома. Вестник РАМН. 2003;(7):31–4. [Reshetnyak TM, Alekberova ZS, Aleksandrova EN i dr. Klinicheskie aspekty antifosfolipidnogo sindroma. Vestnik RAMN. 2003;(7):31–4.]</p><p>Решетняк ТМ, Раденска-Лоповок СГ, Александрова ЕН и др.</p><p>Повреждение легких при антифосфолипидном синдроме. Общая реаниматология. 2005;1(5):34–43. [Reshetnyak TM, Radenska-Lopovok SG, Aleksandrova YeN, et al. Lung Pathology in Antiphospholipid Syndrome. Obshchaya reanimatologiya. 2005;1(5):34–43.]</p><p>Решетняк ТМ, Котельникова ГП, Фомичева ОА и др. Кардиологические аспекты антифосфолипидного синдрома. Часть1. Клапанные поражения сердца при первичном и вторичном антифосфолипидном синдроме и системной красной волчанке. Кардиология. 2002;8:38–43. [Reshetnyak TM, Kotel'nikova GP, Fomicheva OA, et al. Kardiologicheskie aspekty antifosfolipidnogo sindroma. Chast'1. Klapannye porazheniya serdtsa pri pervichnom i vtorichnom antifosfolipidnom sindrome i sistemnoi krasnoi volchanke. Kardiologiya. 2002;8:38–43.]</p><p>Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8. DOI: http://dx.doi.org/10.1182/blood-2011-03-340232.</p><p>Danowski A, de Azevedo MN, de Souza Papi JA, Petri MA. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1195–9. DOI: http://dx.doi.org/10.3899/jrheum.081194.</p><p>Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41(8):924–9. DOI: http://dx.doi.org/10.1093/rheumatology/41.8.924.</p><p>Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560–7.</p><p>Решетняк ТМ, Алекберова ЗС, Котельникова ГП и др. Выживаемость и прогностические факторы риска смерти при антифосфолипидном синдроме: результаты 8-летнего наблюдения. Терапевтический архив. 2003;75(5):46–51. [Reshetnyak TM, Alekberova ZS, Kotelnikova GP, et al. Survival and prognostic factors of death risk in antiphospholipid syndrome: results of 8-year follow-up. Terapevticheskii arkhiv. 2003;75(5):46–51.]</p><p>Раденска-Лоповок СГ, Решетняк ТМ. Патология сосудов при антифосфолипидном синдроме. Архив патологии. 2002;64(1):54–7. [Radenska-Lopovok SG, Reshetnyak TM. Patologiya sosudov pri antifosfolipidnom sindrome. Arkhiv patologii. 2002;64(1):54–7.]</p><p>Levine SR, Brey RL, Tilley BC, et al.; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576–84. DOI: http://dx.doi.org/10.1001/jama.291.5.576.</p><p>Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study. Lancet Neurol. 2009;8(11):998–1005. DOI: http://dx.doi.org/10.1016/S1474-4422(09)70239-X.</p><p>Berkun Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127(2):414–20. DOI: http://dx.doi.org/10.1016/j.jtcvs.2003.07.016.</p><p>Massoudy P, Cetin SM, Thielman M, et al. Antiphospholipid syndrome in cardiac surgery-an underestimated coagulation disorder? Eur J Cardiothorac Surg. 2005;28(1):133–7. DOI: http://dx.doi.org/10.1016/j.ejcts.2004.12.062.</p><p>Lechner K, Simonitsch I, Haselböck J, et al. Acquired immune-mediated thrombophilia in lymphoproliferative disorders. Leuk Lymphoma. 2011 Oct;52(10):1836–43. DOI: 10.3109/10428194.2011.580474. Epub 2011 Jul 18.</p><p>Diz-Kücükkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98(6):1760–4. DOI: 10.1182/blood.V98.6.1760.</p><p>Kosaka M, Takahashi N, Saitoh H, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in a patient with antiphospholipid antibodies and Charcot-Marie-Tooth disease. Intern Med. 2011;50(5):487–93. DOI: http://dx.doi.org/10.2169/internalmedicine.50.4300.</p><p>Scaramucci L, Giovannini M, Niscola P, et al. IgA-induced autoimmune hemolytic anemia in a patient with antiphospholipid syndrome. Asian J Transfus Sci. 2012;6(2):188. DOI: 10.4103/0973-6247.98950.</p><p>D’Cruz D. Renal manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep. Feb 2009;11(1):52–60. DOI: http://dx.doi.org/10.1007/s11926-009-0008-2.</p><p>Mondragon-Ramirez G, Bochicchio T, García-Torres R, et al. Recurrent renal thrombotic angiopathy after kidney transplantation in two patients with primary antiphospholipid syndrome (PAPS). Clin Transplant. 1994;8(2 Pt 1):93–6.</p><p>Amigo MC, Garcia-Torres R, Robles M, et al. Renal involvement in primary antiphospholipid syndrome. J Rheumatol. 1992 Aug;19(8):1181–5.</p><p>Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80(4):614–20.</p></div><br />


Рецензия

Для цитирования:


Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. https://doi.org/10.14412/1995-4484-2014-56-71

For citation:


Reshetnyak T.M. ANTIPHOSPHOLIPID SYNDROME: DIAGNOSIS AND CLINICAL MANIFESTATIONS (A LECTURE). Rheumatology Science and Practice. 2014;52(1):56-71. (In Russ.) https://doi.org/10.14412/1995-4484-2014-56-71

Просмотров: 7683


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)